SERB acquires BTG to expand its treatment portfolio for unmet medical needs

pharmafile | March 2, 2021 | News story | Manufacturing and Production BTG, SERB, specialty pharmaceuticals 

SERB Specialty Pharmaceuticals has purchased BTG Specialty Pharmaceuticals, a division of Boston Scientific that develops treatments with critical conditions, for an undisclosed fee.

The acquisition will transform BTG into a specialty pharmaceutical platform with around 400 employees based in 11 offices, new manufacturing capabilities, and a wider commercial presence across worldwide pharmaceutical markets.

BTG currently provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They have polyclonal antibody development and manufacturing facilities in Wales, Australia, and Utah in the US. 

The company’s products include antidotes to counteract certain snake venoms and the toxicity associated with some heart and cancer medications. Its portfolio also includes emergency care products including CroFab, Voraxaze, and DigiFab. These products are sold primarily in the United States, although the EMA accepted for review a marketing authorisation application for Voraxaze last year. 

SERB is a European specialty pharmaceutical group. It owns a variety of treatments aimed at continuing the availability of life-saving medicines to answer unmet medical needs.

Jeremie Urbain, CEO of SERB, said: “BTG Specialty Pharmaceuticals and SERB are an excellent strategic fit, with complementary portfolios, geographies, and capabilities. The combined company is now a truly global specialty pharmaceutical business with a diversified portfolio of critical care medicines and a growing presence in rare diseases. This creates a platform for growth and broadens the scope for further strategic acquisitions.”

Anthony Higham, President of BTG, added: “Joining SERB will allow BTG Specialty Pharmaceuticals to reach its full potential, expanding our offering to customers in the US and accelerating our European expansion plans. Together we will make an even greater impact in the lives of patients and the people who care for them.”

Jack Goddard

Related Content


BTG acquires promising oncology pipeline in Galil Medical takeover

BTG (LSE: BTG) has announced that is has agreed to acquire Galil Medical, a leading …

FDA image

BTG gets FDA nod

UK healthcare group BTG has received approval from the FDA for a new type of …

Astrazeneca image

AstraZeneca and BTG sepsis drug fails

AstraZeneca’s pipeline has suffered another blow with the troubled company halting development of an investigational …

Latest content